Park Avenue Securities LLC Has $938,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Park Avenue Securities LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,480 shares of the biopharmaceutical company’s stock after selling 539 shares during the period. Park Avenue Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $938,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Brighton Jones LLC grew its stake in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 16.5% in the fourth quarter. Kingsview Wealth Management LLC now owns 1,002 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 142 shares in the last quarter. Kestra Private Wealth Services LLC grew its stake in Regeneron Pharmaceuticals by 12.9% in the fourth quarter. Kestra Private Wealth Services LLC now owns 1,926 shares of the biopharmaceutical company’s stock valued at $1,372,000 after purchasing an additional 220 shares in the last quarter. Savant Capital LLC grew its stake in Regeneron Pharmaceuticals by 21.2% in the fourth quarter. Savant Capital LLC now owns 985 shares of the biopharmaceutical company’s stock valued at $701,000 after purchasing an additional 172 shares in the last quarter. Finally, Essex Financial Services Inc. grew its stake in Regeneron Pharmaceuticals by 9.6% in the fourth quarter. Essex Financial Services Inc. now owns 332 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 29 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $521.84 on Friday. The stock has a market capitalization of $56.34 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The company’s 50-day moving average is $563.74 and its 200-day moving average is $651.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the company earned $9.55 EPS. The company’s revenue was down 3.7% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent analyst reports. Guggenheim reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research note on Monday, June 2nd. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $836.48.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.